(Q28480564)

2

0 references

Cheng Wu

3

0 references

Jian Lu

4

0 references

Shan-Shan Zhang

5

0 references

Jia Guo

6

0 references

Shun-Quan Wu

7

0 references

Xiao-Fei Ye

8

0 references

Jin-Fang Xu

9

0 references

Jia He

Creative Commons Attribution 4.0 International

10

0 references

language of work or name

English

0 references

publication date

20 June 2012

3 references

19 March 2019

24 March 2019

20 August 2019

3 references

19 March 2019

24 March 2019

20 August 2019

7

0 references

issue

6

0 references

page(s)

e39062

0 references

copyright license

3 references

Europe PubMed Central

19 March 2019

Europe PubMed Central

24 March 2019

Europe PubMed Central

on focus list of Wikimedia project

20 August 2019

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

Tesofensine – a novel potent weight loss medicine

19 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

19 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

Obesity management interventions: a review of the evidence

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

The interpretation of random-effects meta-analysis in decision models.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

Successful weight loss maintenance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

Overweight, obesity, and health risk

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

Annual Deaths Attributable to Obesity in the United States

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

The obese older female patient: CV risk and the SCOUT study

2 June 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039062

Body weight, cardiovascular risk factors, and coronary mortality. 15-year follow-up of middle-aged men and women in eastern Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039062

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039062

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039062

Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039062

Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039062

Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039062

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039062

X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039062

Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039062

Effect of orlistat on cardiovascular disease risk in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039062

Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0039062

Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

The Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

Long-term weight loss with sibutramine: a randomized controlled trial

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

The continuing epidemics of obesity and diabetes in the United States

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3380040

Evaluation of a primary care-oriented brief counselling intervention for obesity with and without orlistat

27 November 2018

1 reference

12 December 2020

Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

1 reference

12 December 2020

Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity

1 reference

12 December 2020

Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification

1 reference

12 December 2020

Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study

1 reference

12 December 2020

Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women

1 reference

12 December 2020

Beneficial health effects of modest weight loss

1 reference

12 December 2020

Fluoxetine: a randomized clinical trial in the treatment of obesity

1 reference

12 December 2020